News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Gemmus Pharma to Present New Data at 26th Annual International Society for Antiviral Research (ICAR) Meeting in San Francisco, May 13



4/22/2013 6:33:38 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Gemmus Pharma Inc. ("Gemmus") will present results from its initial studies designed to evaluate the use of GP1001 in influenza at the 26th International Conference on Antiviral Research (ICAR) in San Francisco on May 13 in the afternoon session. The talk, titled “GP1001: a host targeted influenza therapy,” will be given by Daryl Faulds, Ph.D., Co-Founder and Chief Executive Officer of Gemmus, a privately held drug development company.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES